EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen ( BPaMZ ) for Pulmonary Drug‐Resistant Tuberculosis

Pauline Howell iD, Antonio Lombardi iD, William Brumskine iD, Lali Mikiashvili iD, Kim Boekelheide iD, Joanna Moreira, Alda Holsta, Matthew Betteridge, Lindsay Thompson iD, Angela Crook iD, Paul Bruinenberg, Maria Beumont und 2 weitere

Clinical Pharmacology & Therapeutics · 2026-08 · 120 (2) · 501-509

DOI: 10.1002/cpt.70363 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 18.06.2026. Verfasst von Pauline Howell und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Health Research Unit (CHRU), Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Spermatogenesis, Tuberculosis, Multidrug-Resistant, Nitroimidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone assessments. This phase 2 clinical trial assessed testicular safety of therapy with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in 26 adult males with drug‐resistant tuberculosis recruited from South Africa and Georgia. The study included 26 weeks of treatment followed by 52 weeks of safety monitoring until study week 78. The primary endpoint measured change in total sperm count from baseline at week 26, with secondary endpoints evaluating sperm concentration, semen volume, and reproductive hormone concentrations. Results demonstrated favorable testicular safety outcomes. Mean total sperm count increased from 48.8 to 68.8 × 10 6 per ejaculate by week 26. Fifteen participants (68%) showed increased sperm counts, while 17 (77%) exhibited higher sperm concentrations from baseline to week‐26 Thirteen participants (59%) experienced ≥ 50% improvement in both parameters. Two participants demonstrated > 50% decreases in total sperm count; however, sperm concentration reductions were < 50%, suggesting low semen volume as a factor. Testosterone levels increased from baseline, peaking at week 44, while inhibin B demonstrated steady increases, peaking at week 78. Follicle‐stimulating hormone and luteinizing hormone remained stable throughout the study period. All assessable participants achieved sputum culture conversion by week 12. Pharmacokinetic analysis revealed no correlation between pretomanid plasma concentrations and sperm count changes. These findings provide reassurance that pretomanid does not impair human spermatogenesis nor disrupt reproductive hormone homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsSpermatogenesisTuberculosis, Multidrug-ResistantNitroimidazolesTuberculosis, PulmonaryMaleHumansAdultSperm CountYoung AdultInhibinsMiddle AgedLuteinizing HormoneTestisSouth AfricaFollicle Stimulating Hormone

Substanzen

Antitubercular AgentspretomanidNitroimidazolesInhibinsinhibin BLuteinizing HormoneFollicle Stimulating Hormone

Autor:innen und Institutionen

  • Clinical Health Research Unit (CHRU), Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
  • TB Alliance, New York, New York, USA.
  • The Aurum Institute NPC, Rustenburg, South Africa.
  • Department of Medicine, School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia.
  • Brown University, Providence, Rhode Island, USA.

ORCID-Profile: Pauline Howell, Antonio Lombardi, William Brumskine, Lali Mikiashvili, Kim Boekelheide, Lindsay Thompson, Angela Crook, Francesca Conradie

Förderung

  • FIC NIH HHS

Zitieren

APA

Howell, P., Lombardi, A., Brumskine, W., Mikiashvili, L., Boekelheide, K., Moreira, J., Holsta, A., Betteridge, M., Thompson, L., Crook, A., Bruinenberg, P., Beumont, M., Sun, E., & Conradie, F. (2026). Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen ( BPaMZ ) for Pulmonary Drug‐Resistant Tuberculosis. Clinical Pharmacology & Therapeutics, 120(2), 501-509. https://doi.org/10.1002/cpt.70363

Vancouver

Howell P, Lombardi A, Brumskine W, Mikiashvili L, Boekelheide K, Moreira J, et al. Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen ( BPaMZ ) for Pulmonary Drug‐Resistant Tuberculosis. Clinical Pharmacology & Therapeutics. 2026;120(2):501-509. doi:10.1002/cpt.70363

BibTeX
@article{Howell2026,
  author = {Howell, Pauline and Lombardi, Antonio and Brumskine, William and Mikiashvili, Lali and Boekelheide, Kim and Moreira, Joanna and Holsta, Alda and Betteridge, Matthew and Thompson, Lindsay and Crook, Angela and Bruinenberg, Paul and Beumont, Maria and Sun, Eugene and Conradie, Francesca},
  title = {Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen ( BPaMZ ) for Pulmonary Drug‐Resistant Tuberculosis},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {2},
  pages = {501--509},
  doi = {10.1002/cpt.70363}
}
Kostenlos starten →